DOJ Reschedules Cannabis, Sets June 29 Hearing
DOJ Reschedules Cannabis to Schedule III and sets an expedited June 29, 2026 hearing, concentrating regulatory risk for marijuana stocks.
KEY TAKEAWAYS
- DOJ rescheduled qualifying FDA-approved and state-licensed marijuana products to Schedule III on April 23, 2026.
- The order fast-tracks DEA registration and eases research barriers for state medical suppliers.
- An expedited administrative hearing is set for June 29, 2026, concentrating regulatory risk for marijuana stocks.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
The Department of Justice rescheduled cannabis to Schedule III on April 23, 2026, easing research restrictions, fast-tracking DEA registration for state-licensed medical suppliers, and opening an expedited administrative hearing for broader reclassification on June 29, 2026.
Scope of Rescheduling and Regulatory Impact
The order moves qualifying FDA-approved drug products containing marijuana, marijuana extracts, and marijuana-derived compounds such as delta-9 THC into Schedule III. It extends this classification to products manufactured, distributed, or dispensed under state-issued medical marijuana licenses, effectively creating a Schedule III category for these items under federal law.
Marijuana that is not FDA-approved or produced under a state license remains classified as Schedule I, subject to federal criminal and administrative sanctions. Products reclassified as Schedule III must comply with federal rules governing handlers, including security, disposal, and labeling requirements.
Under the Controlled Substances Act, Schedule I drugs have a high potential for abuse and no accepted medical use, examples being heroin and LSD. Schedule III drugs have a lower dependence potential and accepted medical use, including ketamine and anabolic steroids.
State-licensed manufacturers, distributors, and dispensers become eligible for expedited DEA registration, which may reduce federal barriers to research and operations. The change eases federal constraints on medical research for qualifying products while maintaining controls on non-approved items. Industry observers noted the potential for lower tax burdens on state-licensed dispensaries.
Regulatory Process and Timeline
Acting Attorney General Todd Blanche signed the rescheduling order on April 23, 2026, exercising authority under the Controlled Substances Act. The DOJ and DEA terminated prior 2024 proceedings, published a new Federal Register notice, and scheduled an expedited administrative hearing for June 29, 2026, to consider broader marijuana rescheduling.
The order implements President Trump’s December 18, 2025, executive order directing the attorney general to accelerate marijuana rescheduling. It cites a 2023 scientific review by HHS and the FDA, along with a 2024 DOJ proposal, as the legal and scientific basis. The department framed the action as fulfilling obligations under the Single Convention on Narcotic Drugs.
The order does not legalize or decriminalize marijuana federally. By compressing the rulemaking schedule and setting a near-term hearing, the Justice Department has created a concentrated policy window that concentrates regulatory risk and decision points for investors, potentially affecting approaches to marijuana stocks.
"This rescheduling action allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information," Acting Attorney General Blanche said in a DOJ statement.
The expedited hearing follows earlier 2024 rulemaking efforts that began with a May 21, 2024, notice of proposed rulemaking and an August 29, 2024, notice of hearing. The new schedule accelerates the process with firm deadlines.
The June 29 hearing will consider broader rescheduling beyond the current scope, but the outcome remains pending.
